GRI Bio, Inc.

📍 San Diego, United States🗓 Founded 2009👥 12 employees💰 Last funded Jan 2014
Biotechnology🌐 gribio.com
Website LinkedIn
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant NKT (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2009
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
South Africa
1
Frequently asked questions
Who invested in GRI Bio, Inc.?
GRI Bio, Inc. has 1 investors on record on gritt.io, 1 mid-stage.
When did GRI Bio, Inc. last raise funding?
The most recent investment in GRI Bio, Inc. recorded on gritt.io was in January 2014.
When was GRI Bio, Inc. founded?
GRI Bio, Inc. was founded in 2009.
What industry is GRI Bio, Inc. in?
GRI Bio, Inc. operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is GRI Bio, Inc. based?
GRI Bio, Inc. is headquartered in San Diego, United States.